Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 2/2017

01-06-2017 | Hepatitis B (J Lim, Section Editor)

Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection

Authors: Mohit Mittal, Ke-Qin Hu

Published in: Current Hepatology Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

The purpose of this review is to discuss the clinical implications of occult hepatitis B virus infection (OBI) and management options.

Recent Findings

Data regarding the role of OBI as a co-infection and its ability to facility progression of cirrhosis and hepatocellular carcinoma remain conflicting. In a recent meta-analysis, those with chronic hepatitis C and occult hepatitis B co-infection were found to be at increased risk for development of hepatocellular carcinoma. There remains limited data on how to manage these patients to prevent disease progression.

Summary

OBI refers to the presence of hepatitis B viral (HBV) DNA in serum or hepatocytes in the absence of detectable HBV surface antigen (HBsAg) with or without serological markers of previous exposure. As our understanding of the virology has progressed, so has our understanding of the clinical implications of OBI. Despite the growing evidence of the clinical implications of OBI, there are also several conflicting reports in the literature. After years of research, we have further understanding of the pathogenesis of OBI, but many questions remain unanswered. What we do know is that what was once felt to be a relatively innocuous entity is now regarded as a clinically very relevant disease process requiring appropriate assessment and individualized clinical management.
Literature
1.
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–9.CrossRefPubMed
2.
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.CrossRefPubMed
3.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652–7.CrossRefPubMed
4.
Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology. 1998;27:1736–42.CrossRefPubMed
5.
Gerlich WH. Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy. Intervirology. 2014;57:202–11.CrossRefPubMed
6.
Stramer SL, Notari EP, Krysztof DE, Dodd RY. Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety? Transfusion. 2013;53:2449–58.CrossRefPubMed
7.
Allain JP, Mihaljevic I, Gonzalez-Fraile MI, Gubbe K, Holm-Harritshøj L, Garcia JM, et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion. 2013;53:1405–15.CrossRefPubMed
8.
Coppola N, Loquercio G, Tonziello G, Azzaro R, Pisaturo M. HBV transmission from an occult carrier with five mutations the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient. J Clin Virol. 2013;58:315–7.CrossRefPubMed
9.
Furuta RA, Kondo Y, Saito T, Tomita M, Oka K, Kishimoto Y. Transfusions of red blood cells from an occult hepatitis B virus carrier without apparent signs of transfusion-transmitted hepatitis B infection. Transfus Med. 2008;18:379–81.CrossRefPubMed
10.
Su TH, Chen PJ, Chen TC, Cheng HR, Li L, Lin KS, et al. The clinical significance of occult hepatitis B transfusion in Taiwan—a look-back study. Transfus Med. 2011;21:33–41.CrossRefPubMed
11.
12.
Fontenele AM, Filho NS, Ferreira AS. Occult hepatitis B in patients on hemodialysis: a review. Ann Hepatol. 2013;12:527–31.PubMed
13.
Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004;40:1072–7.CrossRefPubMed
14.
Yoo JH, Hwang SG, Yang DH, Son MS, Kwon CI, Ko KH. Prevalence of occult hepatitis B virus infection in hemodialysis patients. Korean J Gastroenterol. 2013;61:209–14.CrossRefPubMed
15.
Wong PN, Fung TT, Mak SK, Lo KY, Tong GM, Wong Y, et al. Hepatitis B virus infection in dialysis patients. J Gastroenterol Hepatol. 2005;20:1641–51.CrossRefPubMed
16.
Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin Dial. 2008;21:440–6.CrossRefPubMed
17.
Centers for Disease Control and Prevention (CDC). Hepatitis-control measures for hepatitis B in dialysis centers. In: Hepatitis surveillance report no. 41. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service, CDC; 1977:12–17.
18.
Moyer LA, Alter MJ, Favero MS. Hemodialysis-associated hepatitis B; revised recommendations for serologic screening. Semin Dial. 1990;3:201–4.CrossRef
19.
Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol. 2013;35:39–52.CrossRefPubMed
20.
Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22–6.CrossRefPubMed
21.
Samuel D, Forns X, Berenguer M, Trautwein C, Burroughs A, Rizzetto M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol. 2006;45:127–43.CrossRefPubMed
22.
Chazouillères O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, et al. “Occult” hepatitis B virus as source of infection in liver transplant recipients. Lancet. 1994;343:142–6.CrossRefPubMed
23.
Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology. 1997;113:1668–74.CrossRefPubMed
24.
Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95:960–5.CrossRefPubMed
25.
Song ZL, Chi YJ, Zhen WP, Teng DH, Zheng H. Application of nucleoside analogues to liver transplant recipients with hepatitis B. World J Gastroenterol. 2015;21:12091–100.CrossRefPubMedPubMedCentral
26.
Kwon CI, Hwang SG, Shin SJ, Chang SW, Kim SY, Ko KH, et al. Occult hepatitis B virus infection in pregnant woman and its clinical implication. Liver Int. 2008;28:667–74.CrossRefPubMed
27.
Maldonado-Rodriguez A, Cevallos AM, Rojas-Montes O, Enriquez-Navarro K, Alvarez-Muñoz MT, Lira R. Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: a review of prevalence, diagnosis and clinical significance. World J Hepatol. 2015;7:253–60.CrossRefPubMedPubMedCentral
28.
Filippini P, Coppola N, Pisapia R, Scolastico C, Marrocco C, Zaccariello A, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS. 2006;20:1253–60.CrossRefPubMed
29.
• Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol. 2014;6:384–93. Important review about immunosuppressed patients with occult hepatitis B infection.
30.
Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, et al. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol. 2015;21:11931–40.CrossRefPubMedPubMedCentral
31.
Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol. 2013;59:696–700.CrossRefPubMed
32.
Sagnelli E, Imparato M, Coppola N, Pisapia R, Sagnelli C, Messina V, et al. Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: a multicenter study. J Med Virol. 2008;80:1547–53.CrossRefPubMed
33.
Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45:238–44. Recent meta-analysis of risk for progression to cirrhosis in those with occult hepatitis B. CrossRefPubMed
34.
•• Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, Farinati F, Missale G, Smedile A, Tiribelli C, Villa E, Raimondo G. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology. 2004;126(1):102–10.
35.
Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer. 2006;106:1326–30.CrossRefPubMed
36.
Obika M, Shinji T, Fujioka S, Terada R, Ryuko H, Lwin AA, et al. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study. Intervirology. 2008;51:59–68.CrossRefPubMed
37.
Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl. 2008;14:534–40.CrossRefPubMed
38.
Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54:434–42.CrossRefPubMedPubMedCentral
39.
•• Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32:231–40. Recent meta-analysis of risk of development of HCC in those with occult hepatitis B.
40.
Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature. 1991;351:317–20.CrossRefPubMed
41.
Tamori A, Yamanishi Y, Kawashima S, Kanehisa M, Enomoto M, Tanaka H, et al. Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Cancer Res. 2005;11:5821–6.CrossRefPubMed
42.
Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogeneis. 2011;32:1122–32.CrossRef
43.
44.
Fallot G, Neuveut C, Buendia MA. Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol. 2012;2:467–73.CrossRefPubMed
45.
46.
Matsuoka S, Nirei K, Tamura A, Nakamura H, Matsumura H, Oshiro S, et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology. 2008;51:352–61.CrossRefPubMed
47.
Arababadi MK, Nasiri Ahmadabadi B, Kennedy D. Current information on the immunologic status of occult hepatitis B infection. Transfusion. 2012;52:1819–26.CrossRefPubMed
48.
Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004;126:1750–8.CrossRefPubMed
49.
Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology. 2011;54:829–36.CrossRefPubMed
50.
Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL. Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol. 2006;45:553–9.CrossRefPubMed
51.
Paterlini P, Poussin K, Kew M, Franco D, Brechot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology. 1995;21:313–21.PubMed
52.
Gozuacik D, Murakami Y, Saigo K, Chami M, Mugnier C, Lagorce D, et al. Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging. Oncogene. 2001;20:6233–40.CrossRefPubMed
53.
Bläckberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol. 2000;33:992–7.CrossRefPubMed
54.
Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003;37:1172–9.CrossRefPubMed
55.
56.
Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagie JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.CrossRefPubMedPubMedCentral
57.
Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233–40.CrossRefPubMed
58.
Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.CrossRefPubMed
59.
Ahmed A, Keeffe EB. Lamivudine therapy for chemotherapy-induced reactivation of hepatitis B virus infection. Am J Gastroenterol. 1999;94:249–51.CrossRefPubMed
60.
Dai MS, Wu PF, Lu JJ, Shyu RY, Chao TY. Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study. Support Care Cancer. 2004;12:191–6.CrossRefPubMed
61.
Leaw SJ, Yen CJ, Huang WT, Chen TY, Su CW, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83:270–5.CrossRefPubMed
62.
Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol. 2004;99:2369–75.CrossRefPubMed
63.
Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58–62.CrossRefPubMed
64.
Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88:209–15.CrossRefPubMed
65.
Li YH, He YF, Jiang WQ, Wang FH, Lin HX, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106:1320–5.CrossRefPubMed
66.
Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24:1003–16.CrossRefPubMed
67.
Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927–34.CrossRefPubMed
68.
Saab S, Dong MH, Joseph TA, Tong MJ. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology. 2007;46:1049–56.CrossRefPubMed
69.
Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–53.CrossRefPubMed
70.
Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J. 2004;5:325–8.CrossRefPubMed
71.
Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol. 2011;17:3881–7.CrossRefPubMedPubMedCentral
72.
Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30–40.CrossRefPubMed
73.
Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11.CrossRefPubMed
74.
Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011;83:1909–16.CrossRefPubMed
75.
Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.CrossRefPubMed
76.
Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.CrossRefPubMed
77.
Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol. 2009;90:13–23.CrossRefPubMed
78.
Ustün C, Koç H, Karayalcin S, Akyol G, Gürman G, Ilhan O, et al. Hepatitis B virus infection in allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;20:289–96.CrossRefPubMed
79.
Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324–30.CrossRefPubMed
80.
Ma SY, Lau GK, Cheng VC, Liang R. Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation. Leuk Lymphoma. 2003;44:1281–5.CrossRefPubMed
81.
Knöll A, Boehm S, Hahn J, Holler E, Jilg W. Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:925–9.CrossRefPubMed
82.
Hui CK, Sun J, Au WY, Lie AK, Yueng YH, Zhang HY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005;42:813–9.CrossRefPubMed
83.
Michel M, Duvoux C, Hezode C, Cherqui D. Hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still’s disease. J Rheumatol. 2003;30:1624–5.PubMed
84.
Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686–7.CrossRefPubMedPubMedCentral
85.
Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31:118–21.PubMed
86.
Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012;31:931–6.CrossRefPubMed
87.
Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M, BIOGEAS Study Group, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90:359–71.CrossRef
88.
Squadrito G, Spinella R, Raimondo G. The clinical significance of occult HBV infection. Ann Gastroenterol. 2014;27:15–9.PubMedPubMedCentral
89.
Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab based regimens: a serious complication in both HBsAg positive and HBsAg-negative patients. Ann Hematol. 2010;89:255–62.CrossRefPubMed
90.
European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef
91.
92.
Abramson JS, Chung RT. Optimal antiviral prophylaxis against hepatitis B reactivation in patients receiving rituximab-based chemotherapy for lymphoma. JAMA. 2014;312:2505–7.CrossRefPubMed
93.
Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol. 2010;16:5447–51.CrossRefPubMedPubMedCentral
94.
Chemin I, Guillaud O, Queyron PC, Trépo C. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol. 2009;51:824–5.CrossRefPubMed
Metadata
Title
Clinical Implications and Management of Chronic Occult Hepatitis B Virus Infection
Authors
Mohit Mittal
Ke-Qin Hu
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 2/2017
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0339-9

Other articles of this Issue 2/2017

Current Hepatology Reports 2/2017 Go to the issue

Hepatitis B (J Lim, Section Editor)

Management of Chronic Hepatitis B in Children

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

The Causes and Clinical Spectrum of Drug-Induced Cholestatic Liver Injury

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?

Hepatitis B (J Lim, Section Editor)

Ethnic Disparities in Chronic Hepatitis B Infection: African Americans and Hispanic Americans

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits